Back to School: How biopharma can reboot drug development. Access exclusive analysis here

NVX, Baxter alter merger terms

North American Vaccine and BAX reduced by $0.27 to $6.73 the per-share consideration that NVX shareholders

Read the full 160 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE